Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.

Silva-Santos B, Mensurado S, Coffelt SB.

Nat Rev Cancer. 2019 Jun 17. doi: 10.1038/s41568-019-0153-5. [Epub ahead of print] Review.

PMID:
31209264
2.

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.

Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt SB, Kersten K, Vrijland K, Kos K, Ulas T, Song JY, Ooi CH, Rüttinger D, Cassier PA, Jonkers J, Schultze JL, Ries CH, de Visser KE.

Nat Cell Biol. 2019 Apr;21(4):511-521. doi: 10.1038/s41556-019-0298-1. Epub 2019 Mar 18.

PMID:
30886344
3.

The ERBB network facilitates KRAS-driven lung tumorigenesis.

Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, Clark W, Hedley A, Laing S, Coffelt SB, Le Quesne J, Dick C, Vousden KH, Martins CP, Murphy DJ.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2565. doi: 10.1126/scitranslmed.aao2565. Erratum in: Sci Transl Med. 2018 Nov 21;10(468):.

PMID:
29925636
4.

PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor development.

Rumney RMH, Coffelt SB, Neale TA, Dhayade S, Tozer GM, Miller G.

PLoS One. 2017 Dec 8;12(12):e0188591. doi: 10.1371/journal.pone.0188591. eCollection 2017.

5.

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.

Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, Doornebal CW, Hau CS, Wellenstein MD, Salvagno C, Doshi P, Lips EH, Wessels LFA, de Visser KE.

Oncoimmunology. 2017 Jun 19;6(8):e1334744. doi: 10.1080/2162402X.2017.1334744. eCollection 2017.

6.

Macrophages promote the progression of premalignant mammary lesions to invasive cancer.

Carron EC, Homra S, Rosenberg J, Coffelt SB, Kittrell F, Zhang Y, Creighton CJ, Fuqua SA, Medina D, Machado HL.

Oncotarget. 2017 Jan 31;8(31):50731-50746. doi: 10.18632/oncotarget.14913. eCollection 2017 Aug 1.

7.

Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study.

van Baal J, Van de Vijver KK, Coffelt SB, van der Noort V, van Driel WJ, Kenter GG, Buist MR, Lok C.

BJOG. 2017 Feb;124(3):486-494. doi: 10.1111/1471-0528.14425. Epub 2016 Nov 16.

8.

Macrophages and Neutrophils: Regulation of the Inflammatory Microenvironment in Autoimmunity and Cancer.

Rahat MA, Coffelt SB, Granot Z, Muthana M, Amedei A.

Mediators Inflamm. 2016;2016:5894347. Epub 2016 Sep 20. No abstract available.

9.

Neutrophils in cancer: neutral no more.

Coffelt SB, Wellenstein MD, de Visser KE.

Nat Rev Cancer. 2016 Jul;16(7):431-46. doi: 10.1038/nrc.2016.52. Epub 2016 Jun 10. Review.

PMID:
27282249
10.

Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor.

Coffelt SB, de Visser KE.

Immunity. 2016 Apr 19;44(4):722-4. doi: 10.1016/j.immuni.2016.03.014.

11.

Systemic inflammation: Cancer's long-distance reach to maximize metastasis.

Coffelt SB, de Visser KE.

Oncoimmunology. 2015 Aug 17;5(2):e1075694. eCollection 2016 Feb.

12.

Immune-mediated mechanisms influencing the efficacy of anticancer therapies.

Coffelt SB, de Visser KE.

Trends Immunol. 2015 Apr;36(4):198-216. doi: 10.1016/j.it.2015.02.006. Review.

PMID:
25857662
13.

IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, de Visser KE.

Nature. 2015 Jun 18;522(7556):345-348. doi: 10.1038/nature14282. Epub 2015 Mar 30.

14.

Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺ breast cancer.

Doornebal CW, Vrijland K, Hau CS, Coffelt SB, Ciampricotti M, Jonkers J, de Visser KE, Hollmann MW.

Pain. 2015 Aug;156(8):1424-32. doi: 10.1097/j.pain.0000000000000136.

PMID:
25734987
15.

Fibrinogen, an endogenous ligand of Toll-like receptor 4, activates monocytes in pre-eclamptic patients.

Al-ofi E, Coffelt SB, Anumba DO.

J Reprod Immunol. 2014 Jun;103:23-8. doi: 10.1016/j.jri.2014.02.004. Epub 2014 Mar 1.

PMID:
24661950
16.

Cancer: Inflammation lights the way to metastasis.

Coffelt SB, de Visser KE.

Nature. 2014 Mar 6;507(7490):48-9. doi: 10.1038/nature13062. Epub 2014 Feb 26. No abstract available.

PMID:
24572360
17.

Generation of a novel mouse model for the inducible depletion of macrophages in vivo.

Gheryani N, Coffelt SB, Gartland A, Rumney RM, Kiss-Toth E, Lewis CE, Tozer GM, Greaves DR, Dear TN, Miller G.

Genesis. 2013 Jan;51(1):41-9. doi: 10.1002/dvg.22343. Epub 2012 Sep 20.

PMID:
22927121
18.

Monocyte subpopulations from pre-eclamptic patients are abnormally skewed and exhibit exaggerated responses to Toll-like receptor ligands.

Al-ofi E, Coffelt SB, Anumba DO.

PLoS One. 2012;7(7):e42217. doi: 10.1371/journal.pone.0042217. Epub 2012 Jul 27.

19.

Toll-like receptor 3 and suppressor of cytokine signaling proteins regulate CXCR4 and CXCR7 expression in bone marrow-derived human multipotent stromal cells.

Tomchuck SL, Henkle SL, Coffelt SB, Betancourt AM.

PLoS One. 2012;7(6):e39592. doi: 10.1371/journal.pone.0039592. Epub 2012 Jun 22.

20.

The autophagic paradox in cancer therapy.

Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK, Yu J, Sung JJ.

Oncogene. 2012 Feb 23;31(8):939-53. doi: 10.1038/onc.2011.295. Epub 2011 Jul 18. Review.

PMID:
21765470
21.

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.

Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE.

J Clin Invest. 2011 May;121(5):1969-73. doi: 10.1172/JCI44562. Epub 2011 Apr 1.

22.

Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion.

Coffelt SB, Chen YY, Muthana M, Welford AF, Tal AO, Scholz A, Plate KH, Reiss Y, Murdoch C, De Palma M, Lewis CE.

J Immunol. 2011 Apr 1;186(7):4183-90. doi: 10.4049/jimmunol.1002802. Epub 2011 Mar 2.

23.

Use of macrophages to target therapeutic adenovirus to human prostate tumors.

Muthana M, Giannoudis A, Scott SD, Fang HY, Coffelt SB, Morrow FJ, Murdoch C, Burton J, Cross N, Burke B, Mistry R, Hamdy F, Brown NJ, Georgopoulos L, Hoskin P, Essand M, Lewis CE, Maitland NJ.

Cancer Res. 2011 Mar 1;71(5):1805-15. doi: 10.1158/0008-5472.CAN-10-2349. Epub 2011 Jan 13.

24.

Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions.

Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, Biswas SK, Murdoch C, Plate KH, Reiss Y, Lewis CE.

Cancer Res. 2010 Jul 1;70(13):5270-80. doi: 10.1158/0008-5472.CAN-10-0012. Epub 2010 Jun 8.

25.

Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications.

Wu WK, Wang G, Coffelt SB, Betancourt AM, Lee CW, Fan D, Wu K, Yu J, Sung JJ, Cho CH.

Int J Cancer. 2010 Oct 15;127(8):1741-7. doi: 10.1002/ijc.25489. Review.

26.

Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors.

Coffelt SB, Lewis CE, Naldini L, Brown JM, Ferrara N, De Palma M.

Am J Pathol. 2010 Apr;176(4):1564-76. doi: 10.2353/ajpath.2010.090786. Epub 2010 Feb 18. Review.

27.

Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells.

Coffelt SB, Tomchuck SL, Zwezdaryk KJ, Danka ES, Scandurro AB.

Mol Cancer Res. 2009 Jun;7(6):907-15. doi: 10.1158/1541-7786.MCR-08-0326. Epub 2009 Jun 2.

28.

Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia.

Fang HY, Hughes R, Murdoch C, Coffelt SB, Biswas SK, Harris AL, Johnson RS, Imityaz HZ, Simon MC, Fredlund E, Greten FR, Rius J, Lewis CE.

Blood. 2009 Jul 23;114(4):844-59. doi: 10.1182/blood-2008-12-195941. Epub 2009 May 19.

29.

Tumor-associated macrophages: effectors of angiogenesis and tumor progression.

Coffelt SB, Hughes R, Lewis CE.

Biochim Biophys Acta. 2009 Aug;1796(1):11-8. doi: 10.1016/j.bbcan.2009.02.004. Epub 2009 Mar 6. Review.

PMID:
19269310
30.

The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.

Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, Honer zu Bentrup K, Danka ES, Henkle SL, Scandurro AB.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3806-11. doi: 10.1073/pnas.0900244106. Epub 2009 Feb 20.

31.

Tumors sound the alarmin(s).

Coffelt SB, Scandurro AB.

Cancer Res. 2008 Aug 15;68(16):6482-5. doi: 10.1158/0008-5472.CAN-08-0044. Review.

32.

The role of myeloid cells in the promotion of tumour angiogenesis.

Murdoch C, Muthana M, Coffelt SB, Lewis CE.

Nat Rev Cancer. 2008 Aug;8(8):618-31. doi: 10.1038/nrc2444. Epub 2008 Jul 17. Review.

PMID:
18633355
33.

Period-2: a tumor suppressor gene in breast cancer.

Xiang S, Coffelt SB, Mao L, Yuan L, Cheng Q, Hill SM.

J Circadian Rhythms. 2008 Mar 11;6:4. doi: 10.1186/1740-3391-6-4.

34.

Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion.

Coffelt SB, Waterman RS, Florez L, Höner zu Bentrup K, Zwezdaryk KJ, Tomchuck SL, LaMarca HL, Danka ES, Morris CA, Scandurro AB.

Int J Cancer. 2008 Mar 1;122(5):1030-9.

35.

Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses.

Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB.

Stem Cells. 2008 Jan;26(1):99-107. Epub 2007 Oct 4.

36.

Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells.

Zwezdaryk KJ, Coffelt SB, Figueroa YG, Liu J, Phinney DG, LaMarca HL, Florez L, Morris CB, Hoyle GW, Scandurro AB.

Exp Hematol. 2007 Apr;35(4):640-52. Erratum in: Exp Hematol. 2007 Jul;35(7):1153-61.

PMID:
17379074
37.

Integrin-linked kinase: a hypoxia-induced anti-apoptotic factor exploited by cancer cells.

Abboud ER, Coffelt SB, Figueroa YG, Zwezdaryk KJ, Nelson AB, Sullivan DE, Morris CB, Tang Y, Beckman BS, Scandurro AB.

Int J Oncol. 2007 Jan;30(1):113-22.

PMID:
17143519

Supplemental Content

Loading ...
Support Center